𝔖 Bobbio Scriptorium

✦ LIBER ✦

297 Preliminary phase I results of the oral, once-daily anglogenesis inhibitor PTK787/ZK 222584 (PTK/ZK) in combination with chemotherapy for the treatment of metastatic colorectal cancer

✍ Scribed by T. Trabach; A.L. Thomas; C. Bartel; U. Vanhoefer; W.P. Steward; B. Wiedenmann; M. Kowalski; U. Riedel; D. Reitsma; D. Laurent

Book ID: 118620472
Publisher: Elsevier Science
Year: 2003
Tongue: English
Weight: 165 KB
Volume: 1
Category: Article
ISSN: 1359-6349
DOI: 10.1016/s1359-6349(03)90330-2

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

1474 POSTER A phase I, open-label study

1474 POSTER A phase I, open-label study with escalating doses of intravenous PTK787/ZK 222584, a multi-VEGF receptor inhibitor, followed by multiple oral daily dosing to assess the absolute bioavailability of PTK787/ZK 222584 after single and multiple doses in advanced cancer patients

📂 Article 📅 2005 🏛 Elsevier Science 🌐 English ⚖ 134 KB

Vatalanib (PTK787/ZK 222584) in Combinat

Vatalanib (PTK787/ZK 222584) in Combination with FOLFOX4 Versus FOLFOX4 Alone as First-Line Treatment for Colorectal Cancer: Preliminary Results from the CONFIRM-1 Trial

✍ Preeta Tyagi; Edward Chu; Vinay K. Jain 📂 Article 📅 2005 🏛 CIG Media Group, LP. 🌐 English ⚖ 99 KB

A phase I study of the oral vascular end

A phase I study of the oral vascular endothelial growth factor (VEGF) receptor tyrosine kinase inhibitor PTK787/ZK 222584 on a twice daily schedule in patients with advanced cancer

📂 Article 📅 2002 🏛 Elsevier Science 🌐 English ⚖ 143 KB

639 POSTER Phase I/II study of PTK/ZK, a

639 POSTER Phase I/II study of PTK/ZK, a novel, oral angiogenesis inhibitor in combination with FOLFIRI as first-line treatment for patients with metastatic colorectal cancer

📂 Article 📅 2005 🏛 Elsevier Science 🌐 English ⚖ 247 KB

3010 ORAL Final overall survival (OS) re

3010 ORAL Final overall survival (OS) results of CONFIRM 1 (CF1), a randomized, double-blind, placebo-controlled phase III trial in patients with metastatic adenocarcinoma of the colon or rectum (mCRC) receiving first line chemotherapy with oxaliplatin/5-fluorouracil/Leucovorin (FOLFOX 4) and PTK787/ZK 222584 (PTK/ZK) or placebo (PBO)

✍ J.R. Hecht; T. Trarbach; E. Jaeger; J. Hainsworth; R.A. Wolff; K. Lloyd; G. Bodo 📂 Article 📅 2007 🏛 Elsevier Science 🌐 English ⚖ 58 KB